Nasdaq:US$13.30 (+0.08) | HKEX:HK$20.50 (-0.70) | AIM:£2.12 (-0.07)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 6 Apr 2013

AACR 2013: HMPL-504 (savolitinib), a novel, selective and potent cMET inhibitor, is efficacious in primary tumor models of cMET-driven gastric cancer